The Global Chronic Bacterial Prostatitis (CBP) market is currently undergoing a period of significant evolution, driven by a combination of an aging global population, advancements in diagnostic precision, and the pressing challenge of antibiotic resistance. Chronic Bacterial Prostatitis—categorized by the National Institutes of Health as Category II—represents a recurring bacterial...